The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Official Title: A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Study ID: NCT00781911
Brief Summary: Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
ImClone Investigational Site, Los Angeles, California, United States
ImClone Investigational Site, Los Angeles, California, United States
ImClone Investigational Site, Aurora, Colorado, United States
ImClone Investigational Site, Atlanta, Georgia, United States
ImClone Investigational Site, Indianapolis, Indiana, United States
ImClone Investigational Site, Kenner, Louisiana, United States
ImClone Investigational Site, Columbus, Ohio, United States
ImClone Investigational Site, Providence, Rhode Island, United States
ImClone Investigational Site, Nashville, Tennessee, United States
ImClone Investigational Site, Dallas, Texas, United States
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR